Highlights from the week of 22nd June - 29th June Gilead Sciences ( FDA, EU, Approval ) FDA and EC grant approval to Gilead's TRODELVY for the treatment of adults with unresectable, locally advanced, mTNBC Merck ( FDA, Approval ) FDA approves Merck's KEYTRUDA and KEYTRUDA QLEX, each in combination with TRODELVY, for the first-line treatment of adults with unresectable, locally advanced, or metastatic TNBC AbbVie ( EU, Approval ) AbbVie's MAVIRET obtains EC approval to treat acute HCV infection in those aged 3 years and older AstraZeneca ( EU, Approval ) EC provides approval to AstraZeneca and Daiichi Sankyo's ENHERTU as monotherapy to treat adults with unresectable or metastatic HER2-positive IHC3+ solid tumours All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 22nd June – 29th June in the world of pharma and healthcare!

Uncategorized /

Highlights from the Week of 22nd June – 29th June in the world of pharma and healthcare! Read More »